Mainz Biomed N.V. announced the pricing of a follow-on offering to raise approximately $3.0 million in gross proceeds. The offering consists of 2,222,222 units, each priced at $1.35 per unit.
Each unit comprises one ordinary share (or pre-funded warrant) and one Series A warrant to purchase one and one-half ordinary shares. The Series A warrants are immediately exercisable at $1.35 per share and will expire five years from the date of issuance.
Maxim Group LLC is acting as the sole placement agent for the offering, which is expected to close on or about August 5, 2025. This capital raise provides additional funding for Mainz Biomed's ongoing clinical development and commercialization efforts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.